Ads
related to: belimumab lupus nephritis phase 3- What About BENLYSTA?
Could BENLYSTA Be Another Option?
See the Data, Dosing & Resources.
- BENLYSTA Dosing Options
Consider Her Schedule And Needs.
Discover The Option That Fits Her.
- But Why BENLYSTA?
See Clinical Trial Results & More
To Explore BENLYSTA For Yourself.
- BENLYSTA Resource Center
Discover A Library Of Resources
Designed To Inform You. Learn More.
- BENLYSTA Video Library
See Video Stories From Peers &
Dig Into BENLYSTA Patient Profiles.
- BENLYSTA Safety Profile
What Your Patients May Experience.
Learn About Possible Side Effects.
- What About BENLYSTA?
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [8] and Canada, [9] and the European Union [5] to treat systemic lupus erythematosus and lupus nephritis. [10]
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.
Blisibimod was initially developed by Amgen, with Phase I trials demonstrating comparable safety between the blisibimod and placebo treatments. [1] It was subsequently acquired by Anthera Pharmaceuticals, [13] who in 2010 initiated a global Phase II study called PEARL-SC to investigate the efficacy, safety, and tolerability of blisibimod in subjects with systemic lupus erythematosus.
For premium support please call: 800-290-4726 more ways to reach us
Pharmaceutical maker GlaxoSmithKline will begin a phase 3 clinical trial to judge lupus medication Benlysta's effectiveness in treating patients with ANCA-positive vasculitis. The trial, which ...
The proliferative forms of lupus nephritis are associated with a higher risk of progression to end stage kidney disease. [21] Black and Hispanic people with lupus nephritis are more likely to present with severe disease at initial presentation (with more proteinuria and more extensive histopathologic changes) and progress to end stage kidney ...
Ads
related to: belimumab lupus nephritis phase 3